Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®

Growth Hormone Deficiency Clinical Trial

Official title:

A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children Treated With SAIZEN®

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00256126
• Other study ID #: 24531
• Status: Completed
• Phase: Phase 4
• Start date: May 31, 2005
• Est. completion date: September 30, 2007

Study information

• Verified date: March 2018
• Source: Merck KGaA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims at identifying the predictive markers after one month of Saizen therapy in Growth Hormone Deficiency (GHD) and Turner Syndrome children.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 318
• Est. completion date: September 30, 2007
• Est. primary completion date: September 30, 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 16 Years

Eligibility

Inclusion Criteria:

• One of the following diagnoses and candidacy for SAIZEN® therapy:

A) GHD: documented pre-established diagnosis of GHD with a growth hormone (GH) peak response of <10 microgram per liter (mcg/L) with 2 GH stimulation tests, without priming with oestradiol.

B) Turner syndrome: documented pre-established diagnosis by karyotype.

• Prepubertal status according to Tanner Pre-established history of normal thyroid function or adequate substitution for at least 3 months.

• Weight for stature within the population specific normal range (>5th and <95th percentiles) for gender Willingness and ability to comply with the protocol for the duration of the study.

• Parent's or guardian's written informed consent, given before any study related procedure that is not part of the subject's normal medical care, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old enough to read and write, a separate assent form will be given.

Exclusion Criteria:

• Acquired GHD due to central nervous system tumour, trauma, infection, infiltration (documented by imaging), and history of irradiation or cranial surgery

• Previous treatment with GH, growth hormone-releasing hormone (GHRH), anabolic steroids or any treatment affecting growth.

• Previous treatment with corticosteroids, except in case of topical or inhaled corticosteroid administration for atopic disease. Corticosteroids for hormonal substitution are also allowed if the condition and the treatment regimen have been stable for at least 3 months.

• Severe associated pathology affecting growth such as malnutrition, malabsorption, or bone dysplasia.

• Chronic severe kidney disease.

• Chronic severe liver disease.

• Chronic infectious disease.

• Acute or severe illness during the previous 6 months.

• Significant concomitant illness that would interfere with participation or assessment in this study.

• Active malignancy (except non-melanomatous skin malignancies that have undergone surgical excision and/or biopsy, diagnosis and treatment to resolution)

• History or active Idiopathic intra-cranial hypertension (benign intracranial hypertension or pseudo-tumor cerebri).

• Diabetes Mellitus type I & II.

• Any autoimmune disease.

• Previous screening failure in this study.

• Use of an investigational drug or participation in another clinical study within the last three months.

Related Conditions & MeSH terms

• Dwarfism, Pituitary
• Endocrine System Diseases
• Gonadal Dysgenesis
• Growth Hormone Deficiency
• Primary Ovarian Insufficiency
• Syndrome
• Turner Syndrome

Intervention

Drug:
• Saizen
Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
• Saizen
Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.

Locations

Country	Name	City	State
Argentina	Local Medical Information Office	Buenos Aires
Australia	Local Medical Information Office	Sydney
Austria	Local Medical Information Office	Vienna
Canada	Local Medical Information Office	Mississauga
France	Local Medical InformationOffice	Paris
Germany	Local Medical Information Office	Munich
Italy	Local Medical Information Office	Rome
Norway	Local Medical Information Office	Oslo
Russian Federation	Local Medical Information Office	Russia
Singapore	Local Medical Information Office	Singapore
Spain	Local Medical Information Office	Madrid
Sweden	Local Medical Information Office	Stockholm
United Kingdom	Local Medical Information Office	Feltham

Sponsors (1)

Lead Sponsor	Collaborator
Merck KGaA

Countries where clinical trial is conducted

Argentina,  Australia,  Austria,  Canada,  France,  Germany,  Italy,  Norway,  Russian Federation,  Singapore,  Spain,  Sweden,  United Kingdom, 

References & Publications (1)

Stevens A, Clayton P, Tatò L, Yoo HW, Rodriguez-Arnao MD, Skorodok J, Ambler GR, Zignani M, Zieschang J, Della Corte G, Destenaves B, Champigneulle A, Raelson J, Chatelain P. Pharmacogenomics of insulin-like growth factor-I generation during GH treatment — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at Month 1	IGF-1 SDS was calculated using the Elmlinger reference method. Change in within subject IGF-1 levels (standard deviation scores) at Month 1 from Baseline was assessed. Descriptive statistics were determined for the Baseline and Month 1 assessments, and also for the level of change between these two assessments. If either the Baseline or Month 1 IGF-1 level was missing, then the within-subject change in IGF-1 was assumed to be missing.	Baseline, Month 1
Secondary	Change From Baseline in Insulin-like Growth Factor Binding Protein - 3 (IGFBP-3) Level at Month 1		Baseline, Month 1
Secondary	Change From Baseline in Fasting Glucose Levels at Month 1		Baseline, Month 1
Secondary	Change From Baseline in Fasting Insulin Levels at Month 1		Baseline, Month 1
Secondary	Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Month 1	HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter [pmol/L]) * fasting plasma glucose (millimole/liter [mmol/L]) divided by 22.5.	Baseline, Month 1
Secondary	Change From Baseline in Bone Alkaline Phosphatase Levels at Month 1		Baseline, Month 1

External Links

•   Full FDA approved prescribing information can be found here